Drug Interactions between resmetirom and venetoclax

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of breast cancer resistance protein (BCRP) may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. In a study of 11 previously treated non-Hodgkin lymphoma patients, when the potent CYP450 3A4 inhibitor, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor ketoconazole (400 mg daily for 7 days) was coadministered with venetoclax (50 mg single dose), venetoclax peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.3-fold and 6.4-fold, respectively. However, data are not available for sole BCRP inhibitors. Increased venetoclax exposure may potentiate the risk of tumor lysis syndrome, particularly at initiation of therapy and during the dosage ramp-up phase, as well as other adverse effects such as diarrhea, nausea, vomiting, neutropenia, anemia, and thrombocytopenia.

MANAGEMENT: Caution and closer monitoring should be considered if venetoclax is used concomitantly with BCRP inhibitors. Some authorities advise that their coadministration should generally be avoided when venetoclax therapy is initiated and during its dosage titration phase, regardless of indication. If coadministration is required, patients should be monitored closely for signs and symptoms of venetoclax-related adverse effects and the dosage modified as per the manufacturer's recommendations.